Found: 27
Select item for more details and to access through your institution.
Author's Reply to Ma et al.: "Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis".
- Published in:
- 2024
- By:
- Publication type:
- Letter
Immune checkpoint inhibitors plus chemotherapy in first‐line endometrial cancer treatment: Still the era of microsatellites?
- Published in:
- BJOG: An International Journal of Obstetrics & Gynaecology, 2024, v. 131, n. 8, p. 1157, doi. 10.1111/1471-0528.17749
- By:
- Publication type:
- Article
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 3, p. e241215, doi. 10.1001/jamanetworkopen.2024.1215
- By:
- Publication type:
- Article
Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities.
- Published in:
- Vaccines, 2021, v. 9, n. 6, p. 623, doi. 10.3390/vaccines9060623
- By:
- Publication type:
- Article
Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1401214
- By:
- Publication type:
- Article
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 2, p. 1096, doi. 10.3390/ijms24021096
- By:
- Publication type:
- Article
The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 7, p. 3871, doi. 10.3390/ijms23073871
- By:
- Publication type:
- Article
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 2, p. 820, doi. 10.3390/ijms23020820
- By:
- Publication type:
- Article
Olaparib and advanced ovarian cancer: Summary of the past and looking into the future.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1162665
- By:
- Publication type:
- Article
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome.
- Published in:
- Frontiers in Endocrinology, 2019, p. N.PAG, doi. 10.3389/fendo.2019.00365
- By:
- Publication type:
- Article
Letter: be careful of gastrointestinal CMV infection in adverse events from ICIs therapy in solid tumours.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 8, p. 916, doi. 10.1111/apt.17416
- By:
- Publication type:
- Article
Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 3, p. 685, doi. 10.3390/diagnostics12030685
- By:
- Publication type:
- Article
Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1254906
- By:
- Publication type:
- Article
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00232
- By:
- Publication type:
- Article
Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma.
- Published in:
- Biomedicines, 2023, v. 11, n. 2, p. 394, doi. 10.3390/biomedicines11020394
- By:
- Publication type:
- Article
Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day.
- Published in:
- Biomedicines, 2022, v. 10, n. 2, p. 411, doi. 10.3390/biomedicines10020411
- By:
- Publication type:
- Article
How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.844801
- By:
- Publication type:
- Article
Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review.
- Published in:
- Cancers, 2022, v. 14, n. 23, p. 5955, doi. 10.3390/cancers14235955
- By:
- Publication type:
- Article
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.
- Published in:
- Cancers, 2021, v. 13, n. 17, p. 4438, doi. 10.3390/cancers13174438
- By:
- Publication type:
- Article
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
- Published in:
- Cancers, 2019, v. 11, n. 8, p. 1055, doi. 10.3390/cancers11081055
- By:
- Publication type:
- Article
The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer.
- Published in:
- Life (2075-1729), 2022, v. 12, n. 10, p. 1552, doi. 10.3390/life12101552
- By:
- Publication type:
- Article
Comparison of Anti–Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 5, p. e2314144, doi. 10.1001/jamanetworkopen.2023.14144
- By:
- Publication type:
- Article
Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 9, p. 1261, doi. 10.3390/ph16091261
- By:
- Publication type:
- Article
Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 5, p. 476, doi. 10.3390/ph14050476
- By:
- Publication type:
- Article
Androgen receptor, PARP signaling, and tumor microenvironment: the 'perfect triad' in prostate cancer?
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241258443
- By:
- Publication type:
- Article
Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 1, doi. 10.1007/s11523-023-01016-x
- By:
- Publication type:
- Article